dataset · University of Pretoria
The purpose of this research was to develop a 225Ac-targeted alpha therapy delivery vehicle using PLGA-chitosan-folic acid-based nanoparticles for tumour selectivity. 8 to 10 MBq of 225Ac-PSMA617-TFA radiopharmaceuticals were produced. The quality controls were monitored, the radiochemical purity was determined in triplicate using a cut-and-count method, where the segments of the iTLC TSA strips were counted<br>in a gamma well counter in the Francium-221 (221Fr) energy window, 218 keV. The data set includes tables and summaries of the research conducted. This was a prospective quantitative experimental study that included the following experiments:Radiolabeling of 225Ac PSMAPreparation of PLGA nanoparticlesFunctionalising of PLGA nanoparticles with chitosan and folic acidEncapsulation of 225Ac PSMA into PLGA-chitosan-folic acid nanoparticlesIn-vitro drug release<br>
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.25403/upresearchdata.32006382.v1
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
